Four target areas (leptin, ghrelin, mitochondrial uncouplers and growth differentiation factor 15 (GDF15)) were initiated and advanced with obesity constituting the primary therapeutic purpose (Table 2). This evidence concerns the gene GHRL and obesity due to melanocortin 4 receptor deficiency.